

Supporting Information

Table of content

NMR Spectra	5
Figure S1. ¹ H NMR (400 MHz; CDCl ₃) of 2,2-dimethylpentan-3-ol	5
Figure S2. ¹ H NMR (400 MHz; CDCl ₃) of 2,2-dimethylpentan-3-one	5
Figure S3. ¹ H NMR (500 MHz; CDCl ₃) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	6
Figure S4. ¹³ C NMR (125 MHz; CDCl ₃) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	6
Figure S5. ¹ H NMR (400 MHz; (CD ₃) ₂ CO; CF ₃ COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	7
Figure S6. ¹³ C NMR (100 MHz; (CD ₃) ₂ CO; CF ₃ COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	7
Figure S7. ¹ H NMR (500 MHz; CDCl ₃) of (2S(R),3R(S),4R(S),5R(S))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (9)	8
Figure S8. ¹³ C NMR (125 MHz; CDCl ₃) of (2S(R),3R(S),4R(S),5R(S))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (9)	8
Figure S9. ¹ H NMR (500 MHz; CDCl ₃) of dimethyl 2-(1-((2,2-dimethylpentan-3-ylidene)amino)-2,2-dimethylpropyl)succinate (10)	9
Figure S10. ¹³ C NMR (125 MHz; CDCl ₃) of dimethyl 2-(1-((2,2-dimethylpentan-3-ylidene)amino)-2,2-dimethylpropyl)succinate (10)	9
Figure S11. ¹ H NMR (500 MHz; CDCl ₃) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-2-ethylpyrrolidine (11)	10
Figure S12. ¹³ C NMR (125 MHz; CDCl ₃) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-2-ethylpyrrolidine (11)	10
Figure S13. ¹ H NMR (400 MHz, CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2 <i>H</i> -pyrrole 1-oxide (12)	11
Figure S14. ¹³ C NMR (100 MHz, CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2 <i>H</i> -pyrrole 1-oxide (12)	11
Figure S15. ¹ H NMR (500 MHz, CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2 <i>H</i> -pyrrole 1-oxide (14)	12
Figure S16. ¹³ C NMR (125 MHz, CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2 <i>H</i> -pyrrole 1-oxide (14)	12
Figure S17. ¹ H NMR (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of (2R(S),3R(S),4R(S),5S(R))-2,2,5-triethyl-5- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl (1a)	13

Figure S18. ¹³ C NMR (100 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of (2R(S),3R(S),4R(S),5S(R))-2,2,5-triethyl-5- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl (1a)	13
Figure S19. ¹ H NMR (400 MHz; CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	14
Figure S20. ¹³ C NMR (100 MHz; CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	14
Figure S21. ¹ H NMR (500 MHz; CDCl ₃) of (2S(R),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (16)	15
Figure S22. ¹³ C NMR (125 MHz; CDCl ₃) of (2S(R),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (16)	15
Figure S23. ¹ H NMR (400 MHz; CDCl ₃) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (17)	16
Figure S24. ¹³ C NMR (100 MHz; CDCl ₃) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (17)	16
Figure S25. ¹ H NMR (500 MHz; CDCl ₃) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (18)	17
Figure S26. ¹³ C NMR (125 MHz; CDCl ₃) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (18)	17
Figure S27. ¹ H NMR (600 MHz; CDCl ₃) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (20)	18
Figure S28. ¹³ C NMR (150 MHz; CDCl ₃) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (20)	18
Figure S29. ¹ H NMR (400 MHz; CDCl ₃) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (21)	19
Figure S30. ¹³ C NMR (125 MHz; CDCl ₃) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (21)	19
Figure S31. ¹ H NMR (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (23)	20
Figure S32. ¹³ C NMR (75 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (23)	20
Figure S33. ¹ H NMR (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	21
Figure S34. ¹³ C NMR (100 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	21
2D NMR Spectra	22
Figure S35. HMBC (400 MHz; (CD ₃) ₂ CO; CF ₃ COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	22
Figure S36. NOESY (400 MHz; (CD ₃) ₂ CO; CF ₃ COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8)	22
Figure S37. NOESY (600 MHz; CDCl ₃) of (2S(R),3R(S),4R(S),5R(S))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (9)	23
Figure S38. HMBC (400 MHz; CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (12)	23
Figure S39. NOESY (400 MHz; CDCl ₃) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (12)	24
Figure S40. COSY (400 MHz; CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	24
Figure S41. HSQC (400 MHz, CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	25
Figure S42. HMBC (400 MHz, CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	25

Figure S43. NOESY (400 MHz, CDCl ₃) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15).....	26
Figure S44. COSY (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	26
Figure S45. HSQC (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	27
Figure S46. HMBC (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	27
Figure S47. NOESY (400 MHz; CD ₃ OD, Zn/CF ₃ COOH system) of ((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	28
Line shape analysis.....	29
Figure S48. Simulated spectrum for (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15).....	29
Table S1. Parameters of spins system (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15).....	29
Figure S49. Simulated spectrum for mono((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	30
Table S2. Parameters of spins system for mono((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26).....	30
IR Spectra	31
Figure S50. IR (neat) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (8).....	31
Figure S51. IR (neat) of (2S(R),3R(S),4R(S),5R(S))-2,5-di- <i>tert</i> -butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (9).....	31
Figure S52. IR (neat) of dimethyl 2-(1-((2,2-dimethylpentan-3-ylidene)amino)-2,2-dimethylpropyl)succinate (10)	31
Figure S53. IR (KBr) of (2R(S),3R(S),4R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-2-ethylpyrrolidine (11).....	32
Figure S54. IR (KBr) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (12)	32
Figure S55. IR (KBr) of 2,2,5-Triethyl-5- <i>tert</i> -butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl (1a) ..	32
Figure S56. IR(KBr) of (2R(S),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2H-pyrrole 1-oxide (14)	33
Figure S57. IR (neat) of (1S(R),4R(S),5R(S))-2,4-di- <i>tert</i> -butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (15)	33
Figure S58. IR (neat) of (2S(R),3R(S),4R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3,4-bis(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (16)	33
Figure S59. IR (KBr) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (17).....	34
Figure S60. IR (KBr) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (18).....	34
Figure S61. IR (KBr) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (20).....	34
Figure S62. IR (KBr) of (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (21).....	35
Figure S63. IR (neat) of (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (23).....	35
Figure S64. IR (neat) of (2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-3-(((3-(dimethylamino)propyl)carbamoyl)oxy)methyl)-2,5-diethylpyrrolidin-1-oxyl (25).....	35

Figure S65. IR (neat) of mono((2S(R),3R(S),5S(R))-2,5-di- <i>tert</i> -butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (26)	36
XRD Data	37
Figure S66. Crystal structure for (2S(R),3R(S))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (20)	37
Figure S67. Crystal structure for (2S(R),3S(R))-2,5-di- <i>tert</i> -butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (21)	37
EPR Data	38
Figure S68. Reduction profiles of 1a (0.2 mM) in anaerobic conditions in phosphate-citrate-borate buffer (5 mM, pH 7.4) in presence of GSH (5 mM) and ascorbate	38
Figure S69. The plot of the nitroxide 1a first order decay constant k_1 versus ascorbate concentration and the linear fit	38
Figure S70. EPR spectrum of 26 (0.2 mM) in phosphate-citrate-borate buffer (5 mM, pH 7.4).	39
Figure S71. Reduction profiles of 26 (0.2 mM) in anaerobic conditions in phosphate-citrate-borate buffer (5 mM, pH 7.4) in presence of GSH (5 mM) and ascorbate	39
Figure S72. The plot of the nitroxide 26 first order decay constant k_1 versus ascorbate concentration and the linear fit.....	40



Figure S3. ^1H NMR (500 MHz; CDCl_3) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S4. ^{13}C NMR (125 MHz; CDCl_3) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S5. ^1H NMR (400 MHz; $(\text{CD}_3)_2\text{CO}$; CF_3COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S6. ^{13}C NMR (100 MHz; $(\text{CD}_3)_2\text{CO}$; CF_3COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-tert-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S7. ^1H NMR (500 MHz; CDCl_3) of (2S(R),3R(S),4R(S),5R(S))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**9**)




Figure S8. ^{13}C NMR (125 MHz; CDCl_3) of (2S(R),3R(S),4R(S),5R(S))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**9**)




Figure S13. ^1H NMR (400 MHz, CDCl_3) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**12**)




Figure S14. ^{13}C NMR (100 MHz, CDCl_3) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**12**)




Figure S15. ^1H NMR (500 MHz, CDCl_3) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**14**)




Figure S16. ^{13}C NMR (125 MHz, CDCl_3) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**14**)




Figure S17. ^1H NMR (400 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of (2R(S),3R(S),4R(S),5S(R))-2,2,5-triethyl-5-*tert*-butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl




Figure S18. ^{13}C NMR (100 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of (2R(S),3R(S),4R(S),5S(R))-2,2,5-triethyl-5-*tert*-butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl




Figure S19. ^1H NMR (400 MHz; CDCl_3) of (1S(R),4R(S),5R(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S20. ^{13}C NMR (100 MHz; CDCl_3) of (1S(R),4R(S),5R(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S23. ^1H NMR (400 MHz; CDCl_3) of (2S(R),3R(S))-2,5-di-*tert*-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**17**)




Figure S24. ^{13}C NMR (100 MHz; CDCl_3) of (2S(R),3R(S))-2,5-di-*tert*-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**17**)




Figure S25. ^1H NMR (500 MHz; CDCl_3) of (2S(R),3S(R))-2,5-di-*tert*-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**18**)




Figure S26. ^{13}C NMR (125 MHz; CDCl_3) of (2S(R),3S(R))-2,5-di-*tert*-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**18**)




Figure S27. ^1H NMR (600 MHz; CDCl_3) of (2S(R),3R(S))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**20**)




Figure S28. ^{13}C NMR (150 MHz; CDCl_3) of (2S(R),3R(S))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**20**)




Figure S29. ^1H NMR (400 MHz; CDCl_3) of (2S(R),3S(R))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**21**)




Figure S30. ^{13}C NMR (125 MHz; CDCl_3) of (2S(R),3S(R))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**21**)




Figure S31. ^1H NMR (400 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of (2*S*(*R*),3*R*(*S*))-2,5-di-tert-butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (**23**)




Figure S32. ^{13}C NMR (75 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of (2*S*(*R*),3*R*(*S*))-2,5-di-tert-butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (**23**)




Figure S33. ^1H NMR (400 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of ((2S(R),3R(S),5S(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)





Figure S34. ^{13}C NMR (100 MHz; CD_3OD , $\text{Zn}/\text{CF}_3\text{COOH}$ system) of ((2S(R),3R(S),5S(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)



2D NMR Spectra

Figure S35. HMBC (400 MHz; $(\text{CD}_3)_2\text{CO}$; CF_3COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S36. NOESY (400 MHz; $(\text{CD}_3)_2\text{CO}$; CF_3COOH) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)




Figure S37. NOESY (600 MHz; CDCl₃) of (2*S*(*R*),3*R*(*S*),4*R*(*S*),5*R*(*S*))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**9**)




Figure S38. HMBC (400 MHz; CDCl₃) of (2*R*(*S*),3*R*(*S*),4*R*(*S*))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**12**)




Figure S39. NOESY (400 MHz; CDCl₃) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**12**)




Figure S40. COSY (400 MHz, CDCl₃) of (1S(R),4R(S),5R(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S41. HSQC (400 MHz, CDCl₃) of (1*S*(R),4*R*(S),5*R*(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S42. HMBC (400 MHz, CDCl₃) of (1*S*(R),4*R*(S),5*R*(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S43. NOESY (400 MHz, CDCl₃) of (1*S*(R),4*R*(S),5*R*(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S44. COSY (400 MHz; CD₃OD, Zn/CF₃COOH system) of ((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)




Figure S45. HSQC (400 MHz; CD₃OD, Zn/CF₃COOH system) of ((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-((((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)




Figure S46. HMBC (400 MHz; CD₃OD, Zn/CF₃COOH system) of ((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-((((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)





Figure S47. NOESY (400 MHz; CD₃OD, Zn/CF₃COOH system) of ((2S(R),3R(S),5S(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-((((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)



Line shape analysis

The analysis was performed using the gNMR 5.0 software [Budzelaar, P. H. M. "gNMR, version 5.0. 6.0." *Ivorysoft, Nijmegen, Netherlands* (2006).].

Figure S48. Simulated spectrum for (1S(R),4R(S),5R(S))-2,4-di-tert-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Table S1. Parameters of spins system (1S(R),4R(S),5R(S))-2,4-di-tert-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)

#	n	Shift	Width	J[1]	J[2]	J[3]	J[4]	J[5]	J[6]	J[7]	J[8]	J[9]	J[10]	J[11]	J[12]
1	9	0.884	1.53												
2	9	1.200	1.41	-											
3	3	0.921	1.24	-	-										
4	1	1.283	2.94	-	-	7.85									
5	1	1.969	1.72	-	-	7.21	-14.54								
6	3	0.892	1.25	-	-	-	-	-	7.4*						
7	1	0.951*	-	-	-	-	-	-	7.4*	-14.4*					
8	1	1.106*	-	-	-	-	-	-	-	4.31	12.31				
9	1	1.829	1.77	-	-	-	-	-	-	5.18	11.42	-13.57			
10	1	1.955	1.82	-	-	-	-	-	-	-	-	-	-		
11	1	0.126	1.78	-	-	-	-	-	-	-	-	-	-		
12	1	0.768	1.97	-	-	-	-	-	-	-	-	-	-	-4.20	
13	1	1.454	1.70	-	-	-	-	-	-	-	-	-	-	4.56	8.24

*the data is not reliably determined

Figure S49. Simulated spectrum for mono((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)




Table S2. Parameters of spins system for mono((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)

#	n	Shift	Width	J[1]	J[2]	J[3]	J[4]	J[5]	J[6]	J[7]	J[8]	J[9]	J[10]	J[11]	J[12]	J[13]	J[14]	J[15]	J[16]	J[17]	J[18]	J[19]
1	9	1.169	2.45																			
2	9	1.205	2.84	-																		
3	3	1.090	2.25	-	-																	
4	1	1.903	2.89	-	-	7.59																
5	1	2.205	3.33	-	-	7.37	-15.41															
6	3	1.235	2.59	-	-	-	-	-														
7	1	1.933	2.75	-	-	-	-	-	7.43													
8	1	2.409	2.44	-	-	-	-	-	7.25	-15.23												
9	1	2.126	3.73	-	-	-	-	-	-	-	-											
10	1	2.329	3.35	-	-	-	-	-	-	-	-	-13.94										
11	1	2.955	3.92	-	-	-	-	-	-	-	-	13.72	5.99									
12	1	4.355	3.10	-	-	-	-	-	-	-	-	-	-	9.98								
13	1	4.594	3.19	-	-	-	-	-	-	-	-	-	-	4.85	-10.59							
14	1	3.241	4.20	-	-	-	-	-	-	-	-	-	-	-	-	-						
15	1	3.240	2.88	-	-	-	-	-	-	-	-	-	-	-	-	-	-16.26*					
16	1	2.006	2.63	-	-	-	-	-	-	-	-	-	-	-	-	-	4.75	9.92				
17	1	2.005	3.40	-	-	-	-	-	-	-	-	-	-	-	-	-	2.98	8.09	-16.53*			
18	1	3.410	2.85	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.83	10.43		
19	1	3.399	2.62	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.69	2.46	-15.78*	
20	9	3.147	2.47	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

*the data is not reliably determined

IR Spectra




Figure S50. IR (neat) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**8**)**Figure S51.** IR (neat) of (2S(R),3R(S),4R(S),5R(S))-2,5-di-*tert*-butyl-3,4-bis(methoxycarbonyl)-2-ethylpyrrolidine (**9**)**Figure S52.** IR (neat) of dimethyl 2-(1-((2,2-dimethylpentan-3-ylidene)amino)-2,2-dimethylpropyl)succinate (**10**)

Figure S53. IR (KBr) of (2R(S),3R(S),4R(S),5S(R))-2,5-di-tert-butyl-3,4-bis(hydroxymethyl)-2-ethylpyrrolidine (**11**)




Figure S54. IR (KBr) of (2R(S),3R(S),4R(S))-2,5-di-tert-butyl-2-ethyl-3,4-bis(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**12**)




Figure S55. IR (KBr) of 2,2,5-Triethyl-5-tert-butyl-3,4-bis(hydroxymethyl)-pyrrolidine-1-oxyl (**1a**)




Figure S56. IR(KBr) of (2R(S),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)-3,4-dihydro-2H-pyrrole 1-oxide (**14**)




Figure S57. IR (neat) of (1S(R),4R(S),5R(S))-2,4-di-*tert*-butyl-4-ethyl-1-propyl-3-azabicyclo[3.1.0]hex-2-ene (**15**)




Figure S58. IR (neat) of (2S(R),3R(S),4R(S))-2,5-di-*tert*-butyl-2-ethyl-3,4-bis(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**16**)




Figure S59. IR (KBr) of (2S(R),3R(S))-2,5-di-tert-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**17**)




Figure S60. IR (KBr) of (2S(R),3S(R))-2,5-di-tert-butyl-2-ethyl-3-(methoxycarbonyl)-3,4-dihydro-2H-pyrrole 1-oxide (**18**)




Figure S61. IR (KBr) of (2S(R),3R(S))-2,5-di-tert-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**20**)




Figure S62. IR (KBr) of (2S(R),3S(R))-2,5-di-tert-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2H-pyrrole 1-oxide (**21**)




Figure S63. IR (neat) of (2S(R),3R(S))-2,5-di-tert-butyl-2,5-diethyl-3-(hydroxymethyl)pyrrolidin-1-oxyl (**23**)




Figure S64. IR (neat) of (2S(R),3R(S),5S(R))-2,5-di-tert-butyl-3-(((3-(dimethylamino)propyl)carbamoyl)oxy)methyl)-2,5-diethylpyrrolidin-1-oxyl (**25**)





Figure S65. IR (neat) of mono((2*S*(R),3*R*(S),5*S*(R))-2,5-di-*tert*-butyl-2,5-diethyl-3-(((3-(trimethylammonio)propyl)carbamoyl)oxy)methyl)pyrrolidin-1-oxyl) monoiodide (**26**)



XRD Data

Chemical structures of the molecules **20** and **21** obtained by X-ray single crystal diffractometry:

Figure S66. Crystal structure for (2*S*(R),3*R*(S))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**20**)





Figure S67. Crystal structure for (2*S*(R),3*S*(R))-2,5-di-*tert*-butyl-2-ethyl-3-(hydroxymethyl)-3,4-dihydro-2*H*-pyrrole 1-oxide (**21**)



Crystal data **20**: C₁₅H₂₉NO₂, M = 255.39, monoclinic, space group C2/c, at 296 K: a = 20.1597(14), b = 15.1070(10), c = 12.4016(7) Å, β = 119.835(2)°, V = 3276.3(4) Å³, Z = 8, d_{calc} = 1.036 g·cm⁻³, μ = 0.067 mm⁻¹, a total of 26540 (θ_{max} = 28.02°), 3964 I unique (R_{int} = 0.0623), 2877 [I > 2σ(I)], 170 parameters. GooF = 1.001, R₁ = 0.0887, wR₂ = 0.2676 [I > 2σ(I)], R₁ = 0.1107, wR₂ = 0.3048 (all data), max/min diff. peak 1.39/-0.32 e·Å⁻³. CCDC 2312570.

Crystal data **21**: C₁₅H₂₉NO₂, M = 255.39, triclinic, space group P-1, at 296 K: a = 9.5627(8), b = 12.9565(13), c = 13.4896(14) Å, α = 85.641(4), β = 88.100(4), γ = 79.040(3)°, V = 1635.8(3) Å³, Z = 4, d_{calc} = 1.037 g·cm⁻³, μ = 0.067 mm⁻¹, a total of 16573 I (θ_{max} = 25.21°), 5832 unique (R_{int} = 0.0642), 3298 [I > 2σ(I)], 339 parameters. GooF = 1.015, R₁ = 0.0616, wR₂ = 0.1775 [I > 2σ(I)], R₁ = 0.1144, wR₂ = 0.2142 (all data), max/min diff. peak 0.34/-0.18 e·Å⁻³. CCDC 2312569.

EPR Data

Figure S68. Reduction profiles of **1a** (0.2 mM) in anaerobic conditions in phosphate-citrate-borate buffer (5 mM, pH 7.4) in presence of GSH (5 mM) and ascorbate (200 (●), 300 (■) mM). The amplitude of the low-field component of the EPR spectrum was followed, spectrometer settings: frequency, 9.87 GHz; centerfield, 350.6 mT; sweep range, 10 mT; microwave power, 2.0 mW; modulation amplitude, 0.1 mT; time constant, 10.24 ms; and conversion time, 20.48 ms.




Figure S69. The plot of the nitroxide **1a** first order decay constant k_1 versus ascorbate concentration and the linear fit corresponding to $k_2 = (7.0 \pm 2 \times 10^{-5} \text{ M}^{-1} \text{ s}^{-1})$.




Figure S70. EPR spectrum of **26** (0.2 mM) in distilled water. Spectrometer settings: frequency, 9.87 GHz; microwave power, 5.0 mW; modulation amplitude, 0.05 mT; time constant, 50–100 ms; and conversion time, 5.12 ms.




Figure S71. Reduction profiles of **26** (0.2 mM) in anaerobic conditions in phosphate-citrate-borate buffer (5 mM, pH 7.4) in presence of GSH (5 mM) and ascorbate (100 (●), 200 (■) and 300 (◆) mM). The amplitude of the low-field component of the EPR spectrum was followed, spectrometer settings: frequency, 9.87 GHz; centerfield, 350.6 mT; sweep range, 10 mT; microwave power, 2.0 mW; modulation amplitude, 0.1 mT; time constant, 10.24 ms; and conversion time, 20.48 ms.




Figure S72. The plot of the nitroxide **26** first order decay constant k_1 versus ascorbate concentration and the linear fit corresponding to $k_2 = (2.0 \pm 0.1 \times) 10^{-3} \text{ M}^{-1}\text{s}^{-1}$.

